Founded by a team of expert immunologists from Stanford University, Paramune develops innovative biologic therapies for inflammatory diseases and cancer.
Paramune focuses on novel molecular mechanisms to treat cancers and autoimmune diseases more effectively. Our targets arise from fundamental new discoveries that provide transformative insights into disease pathology. Our therapeutic molecules are rigorously engineered to engage the identified targets. To that end, we utilize a variety of next-generation biologic formats (such as monoclonal antibodies, bispecifics, engagers and antibody cocktails) to enable our therapeutic candidates to deliver the greatest possible efficacy with outstanding safety profiles. Our approaches target disease mechanisms at the fundamental level, and as a result are anticipated to achieve superior results as compared to current therapeutic approaches.
Paramune was founded in 2020 to advance discoveries made at Stanford University into new medicines for patients with autoimmune diseases. Our founders bring extensive experience in immunology, clinical care, therapeutic development, and company creation.
Paramune’s programs are designed to offer rapid and proven paths to clinical stage development. Paramune’s culture is open, honest, fast-paced, team-centered, and science-focused with flat hierarchies. The company is based in the San Francisco Bay Area, one of the most prolific biotech hubs in the world, and operates R&D labs in San Carlos, California.
Meet our Team.
Paramune is a rapidly growing company that offers opportunities to have a positive impact on human health. We are looking to add motivated, collaborative team members who are excited to advance the development of new treatments for autoimmune disease and cancer. Paramune offers a dynamic work environment with competitive pay and benefits.
Check out the open positions on our Careers page.